GREAT POINT PARTNERS LLC
An institutional investment manager in Greenwich, CT. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1281446.
- Reported value$529.1m
- Positions42
Holdings: 42 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 53.3 | 10.1% | 400,000 | Call | New+400,000 |
| VOR Biopharma IncVOR | COM NEW | 929033207 | 31.3 | 5.9% | 1,700,000 | Reduced−50,000 | |
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 27.2 | 5.1% | 204,314 | New+204,314 | |
| Immunitybio IncIBRX | COM | 45256X103 | 26.3 | 5.0% | 3,000,800 | Put | Unchanged |
| Vera Therapeutics IncVERA | CL A | 92337R101 | 25.8 | 4.9% | 600,836 | Added+401,488 | |
| Zura Bio Ltd | CLASS A ORD SHS | G9TY5A101 | 24.9 | 4.7% | 4,215,930 | Unchanged | |
| Alumis IncALMS | COM | 022307102 | 24.1 | 4.6% | 856,061 | Unchanged | |
| Sol-Gel Technologies Ltd | SHS NEW | M8694L137 | 20.3 | 3.8% | 274,363 | Unchanged | |
| Ultragenyx Pharmaceutical inRARE | COM | 90400D108 | 20.0 | 3.8% | 600,000 | Put | New+600,000 |
| Definium Therapeutics IncDFTX | COM SHS | 24477V105 | 20.0 | 3.8% | 425,000 | New+425,000 | |
| Annexon IncANNX | COM | 03589W102 | 20.0 | 3.8% | 3,500,000 | Added+1,000,000 | |
| Oruka Therapeutics IncORKA | COM | 687604108 | 17.4 | 3.3% | 183,330 | Unchanged | |
| Moonlake ImmunotherapeuticsMLTX | CLASS A ORD | 61559X104 | 16.7 | 3.1% | 855,813 | Added+355,813 | |
| Sagimet Biosciences IncSGMT | COM SER A | 786700104 | 15.7 | 3.0% | 2,029,933 | New+2,029,933 | |
| Contineum Therapeutics IncCTNM | CL A | 21217B100 | 15.1 | 2.9% | 921,481 | Added+121,283 | |
| Immix Biopharma IncIMMX | COM | 45258H106 | 13.2 | 2.5% | 1,277,642 | Added+927,642 | |
| Climb Bio IncCLYM | COM | 28658R106 | 13.0 | 2.5% | 1,000,000 | Reduced−334,130 | |
| Amylyx Pharmaceuticals IncAMLX | COM | 03237H101 | 12.6 | 2.4% | 700,000 | Reduced−1,050,000 | |
| Nektar TherapeuticsNKTR | COM NEW | 640268306 | 12.2 | 2.3% | 175,000 | Reduced−141,453 | |
| Neurogene IncNGNE | COM | 64135M105 | 11.1 | 2.1% | 352,180 | Reduced−147,820 | |
| LB Pharmaceuticals IncLBRX | COM SHS | 50180M108 | 10.3 | 1.9% | 317,221 | Added+17,221 | |
| Opus Genetics IncIRD | COM | 67577R102 | 8.1 | 1.5% | 1,970,187 | Added+1,645,847 | |
| Eupraxia Pharmaceuticals IncEPRX | COM | 29842P105 | 7.9 | 1.5% | 1,200,000 | Unchanged | |
| Bright Minds Biosciences IncDRUG | COM NEW | 10919W405 | 7.7 | 1.5% | 109,603 | Reduced−110,397 | |
| Inflarx NV | COM | N44821101 | 6.8 | 1.3% | 3,046,557 | New+3,046,557 | |
| Relmada Therapeutics IncRLMD | COM | 75955J402 | 5.8 | 1.1% | 842,106 | Unchanged | |
| Jatt II Acquisition Corp | ORD SHS | G50765109 | 5.7 | 1.1% | 500,000 | New+500,000 | |
| Cullinan Therapeutics IncCGEM | COM | 230031106 | 5.5 | 1.0% | 300,000 | Unchanged | |
| Altimmune IncALT | COM NEW | 02155H200 | 5.3 | 1.0% | 1,741,232 | New+1,741,232 | |
| Amanat Acquisition Corp | CL A ORD | G0375M101 | 5.1 | 1.0% | 500,000 | New+500,000 | |
| Rezolute IncRZLT | COM NEW | 76200L309 | 4.9 | 0.9% | 951,809 | Unchanged | |
| Silence Therapeutics plcSLN | ADS | 82686Q101 | 4.9 | 0.9% | 450,000 | Reduced−570,489 | |
| Palisade Bio IncPALI | COM | 696389402 | 4.8 | 0.9% | 2,284,819 | Reduced−1,120,938 | |
| Evommune IncEVMN | COM SHS | 30054Y107 | 4.3 | 0.8% | 325,000 | Unchanged | |
| Scynexis IncSCYX | COM | 811292309 | 3.8 | 0.7% | 944,292 | New+944,292 | |
| Galectin Therapeutics IncGALT | COM NEW | 363225202 | 3.7 | 0.7% | 800,000 | Call | Unchanged |
| Enliven Therapeutics IncELVN | COM | 29337E102 | 3.6 | 0.7% | 70,000 | New+70,000 | |
| Humacyte IncHUMA | COM | 44486Q103 | 2.9 | 0.6% | 3,750,000 | Unchanged | |
| Rein Therapeutics IncRNTX | COM NEW | 00887A204 | 2.7 | 0.5% | 2,575,000 | New+2,575,000 | |
| DBV Technologies S aDBVT | SPONSORED ADS | 23306J309 | 2.6 | 0.5% | 156,906 | New+156,906 | |
| Anavex Life Sciences CorpAVXL | COM NEW | 032797300 | 1.4 | 0.3% | 521,300 | Call | Unchanged |
| Promis Neurosciences IncPMN | COM SHS | 74346M505 | 1.1 | 0.2% | 86,150 | Reduced−285,252 |
Sold out: 13 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Alkermes plc | SHS | G01767105 | 0.0 | 0.0% | 0 | Sold out−50,000 | |
| Apogee Therapeutics Inc | COM | 03770N101 | 0.0 | 0.0% | 0 | Sold out−374,000 | |
| Avalo Therapeutics IncAVTX | COM NEW | 05338F306 | 0.0 | 0.0% | 0 | Sold out−124,666 | |
| Compass Therapeutics IncCMPX | COM | 20454B104 | 0.0 | 0.0% | 0 | Sold out−1,350,000 | |
| Context Therapeutics IncCNTX | COM | 21077P108 | 0.0 | 0.0% | 0 | Sold out−2,238,496 | |
| Immunovant IncIMVT | COM | 45258J102 | 0.0 | 0.0% | 0 | Sold out−545,625 | |
| Jade Biosciences IncJBIO | COM NEW | 008064206 | 0.0 | 0.0% | 0 | Sold out−964,462 | |
| Kalvista Pharmaceuticals Inc | COM | 483497103 | 0.0 | 0.0% | 0 | Sold out−675,000 | |
| Pharvaris N V | COM | N69605108 | 0.0 | 0.0% | 0 | Sold out−82,800 | |
| Scynexis Inc | COM NEW | 811292200 | 0.0 | 0.0% | 0 | Sold out−7,554,347 | |
| Tenax Therapeutics IncTENX | COM NEW | 88032L605 | 0.0 | 0.0% | 0 | Sold out−327,307 | |
| Unicycive Therapeutics IncUNCY | COM NEW | 90466Y202 | 0.0 | 0.0% | 0 | Sold out−796,558 | |
| Zenas Biopharma IncZBIO | COM | 98937L105 | 0.0 | 0.0% | 0 | Sold out−524,066 |
Source: SEC EDGAR, Form 13F-HR, accession 0001172661-26-003750 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.